System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Hsin-An Hou is an expert in Hematology at National Taiwan University Hospital (Taiwan). As of October 2026, ScienceLeadR ranks Hsin-An Hou in the top 1% of experts worldwide for Leukemia. Hsin-An Hou has authored 305 publications, the most recent in 2026, and is an investigator in 15 clinical trials, 6 of them ongoing. SLR score: 1,385 (community average: 125). How the SLR is computed.

LeadR Profile

Hsin-An Hou National Taiwan University Hospital Taiwan
1 385 ScienceLeadR Reputation 1385

Unlock

Register Login
Network Map

Hematology

Subspecialties: Oncology - Genetics

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 2007 - 2026
Source: PubMed

National Taiwan University Hospital

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 305

Citations

Citations: 6 823 1st author: 31 Last author: 23 Unique author: 0

Main journals

Blood 87
Blood Cancer J 19
Leukemia 16
Hemasphere 11
Ann Hematol 10

Best Journals

J Clin Oncol 5
J Hematol Oncol 1
Lancet 1

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Interferon Therapy in Acute Myeloid Leukemia: Biological Rationale, Clinical Evidence, and Future Directions.
PMID 42938803 — cells, microscopy, electron, scanning transmission, leukemia, stem cells, leukemia, myeloid, acute, immunotherapy, leukemia, myeloid, transplants, therapeutics		Cancers (Basel)20260
Prognostic implications of TET2 variant allele frequency in chronic myelomonocytic leukemia: a multicenter study.
PMID 42904085 — gene frequency, leukemia, myelomonocytic, chronic, leukemia, alleles		Blood Neoplasia20260
Divergent Clonal Trajectories of FLT3-ITD in Acute Myeloid Leukemia and Their Clinical and Transcriptomic Associations.
PMID 42770524 — hematology, leukemia, leukemia, myeloid, acute, clonal evolution, leukemia, myeloid, diagnosis, mutation		Hematol Oncol20260
Clinicomolecular features and clonal evolution of KMT2A-PTD AML: prognostic impact of concurrent FLT3-ITD under 2022 ELN risk stratification.
PMID 42642370 — clonal evolution		Blood Cancer J20260
Immune and cytokine landscape differs between cytopenic and proliferative phenotypes in primary myelofibrosis.
PMID 42620871 — cytokines, fibrosis, phenotype, mutation, primary myelofibrosis, cytopenia		Ther Adv Hematol20260

Clinical Studies 15

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 3

By phase:

Phase 3 5
N/A 4
Phase 2 3
Phase 1 2
Phase 2/Phase 3 1

By status:

Completed 5
Recruiting 5
Active not recruiting 2
Not yet recruiting 1
Terminated 1
Unknown 1

By type:

Interventional 11
Observational 4

By Monocentric/Multicentric:

monocentric 5
multicentric2to4 0
multicentric5to9 1
multicentricup10 9

Main Topics

Cohort/Consortium Investigators 1

Ongoing Clinical Trials

6 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib
NCT07623161 — injections, safety, anemia, pharmaceutical preparations, drug therapy, therapeutics, primary myelofibrosis		Phase 3Recruiting2026
A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor na ve Myelofibrosis and Moderate Thrombocytopenia
NCT05980806 — safety, tablets, symptom assessment, janus kinase inhibitors, spleen, primary myelofibrosis, thrombocytopenia		Phase 2Recruiting2024
Clinical Study for the Efficacy and Safety of Ropeginterferon Alfa 2b in Adult COVID 19 Patients With Comorbidities
NCT05808322 — comorbidity, sars-cov-2, safety, dexamethasone, covid-19, centers for disease control and prevention, u.s., severe acute respiratory syndrome-related coronavirus, antiviral agents, infections		Phase 2/Phase 3Not yet recruiting2023
Ropeginterferon Alfa 2b for Early MyelofibrosisDIPSS Low Intermediate 1 Risk Myelofibrosis
NCT05731245 — safety, syringes, primary myelofibrosis		Phase 2Recruiting2023
A Study of PEP07 (Checkpoint Kinase 1 Inhibitor) in Patients With Advanced Cancer
NCT05659732 — cells, pharmaceutical preparations, lymphoma, neoplasms, checkpoint kinase 1, leukemia, leukemia, myeloid, acute, capsules, leukemia, myeloid, gelatin, lymphoma, mantle-cell, therapeutics		Phase 1Recruiting2023

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS